MS News (Y!)

A new study by multiple sclerosis researchers addresses why bone marrow transplantation has positive results in patients with particularly aggressive forms of MS.

A new study by multiple sclerosis researchers at three leading Canadian centers addresses why bone marrow transplantation has positive results in patients with particularly aggressive forms of MS.

Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Up to seven years of clinical trial experience (Phase II and III) and over ...

Many expect good news this week from an FDA decision on new MS pill Tecfidera.

Whether opening up narrow neck veins in people with multiple sclerosis improves symptoms continues to be an unanswered question following mounting evidence from studies.

LONDON (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a leading industry analyst. The French drugmaker won an approval reco...

When Julie Hare was diagnosed with multiple sclerosis , she and her husband Steve asked the same question: What is it?

EDWARDS, Colorado — Can Do Multiple Sclerosis 's sound fiscal management practices and commitment to accountability and transparency has earned it a four-star rating from Charity Navigator, America's largest independent charity evaluator.

LAPLACE – Sharonne Gauthier is a young woman who carries a heavy load, but not without grace — the 33-year-old was officially diagnosed with multiple sclerosis just three years ago but has not let the

EDWARDS, Colorado - Can Do Multiple Sclerosis 's sound fiscal management practices and commitment to accountability and transparency has earned it a four-star rating from Charity Navigator, America's largest independent charity e Copyright 2013 Vail Daily. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Vail Daily Can Do Multiple Sclerosis earns ...

Biogen's MS drug Tecfidera (formerly known as BG-12) got the green light from the EU's CHMP; could FDA approval be next?

Biogen Idec ( BIIB ) recently announced additional patent protection for its oral multiple sclerosis candidate, Tecfidera (dimethyl fumarate). The company said that the US Patent and

By Ben Hirschler LONDON, March 22 - European regulators have recommended approval of two new multiple sclerosis pills from Biogen Idec and Sanofi, both of which are expected to become major sellers. Friday's decision by the European Medicines Agency (EMA) was particularly significant for Biogen, since the U.S. biotech company is still awaiting a verdict on Tecfidera, or BG-12, in the United ...

Sanofi (SAN) won backing from a European advisory panel for its first multiple sclerosis therapy, the tablet Aubagio, a step forward in the French drugmaker’s plan to grab a slice of the $14 billion MS business.

Biogen Idec Inc. (BIIB) , maker of the multiple sclerosis drugs Avonex and Tysabri, won European Union backing for Tecfidera, its first pill for the central nervous system disease.

Today Biogen Idec announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use in the European Union recommending a marketing authorization be granted for TECFIDERA™ as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis .

A cure for multiple sclerosis has not yet been found, but the faculty at one area school took a shot at raising money that could help make life a little easier for those living with the debilitating disease.

A new study found that atrophy of the thalamus, determined with MRI, can help identify which patients with clinically isolated syndrome, a patient's first episode of MS, are at risk for developing clinically definite MS.

A multiple sclerosis sufferer has told how he has had to cancel his life insurance payments to pay the new bedroom tax.

LAS CRUCES —A fundraising walk that will also raise awareness about multiple sclerosis is slated for April 6 in Las Cruces.